Priya B Shete

List of Publications by Year
in descending order

28 papers	713 citations	759233 12 h-index	580821 25 g-index
35 all docs	35 docs citations	35 times ranked	1129 citing authors

#	Article	IF	Citations
1	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
2	Racial/Ethnic Disparities In COVID-19 Exposure Risk, Testing, And Cases At The Subcounty Level In California. Health Affairs, 2021, 40, 870-878.	5.2	102
3	Effect of the Bolsa Familia Programme on the outcome of tuberculosis treatment: a prospective cohort study. The Lancet Global Health, 2019, 7, e219-e226.	6.3	51
4	Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis. BMC Infectious Diseases, 2019, 19, 268.	2.9	48
5	Evaluation of antibody responses to panels of M. tuberculosis antigens as a screening tool for active tuberculosis in Uganda. PLoS ONE, 2017, 12, e0180122.	2.5	27
6	Tuberculosis in Brazil and cash transfer programs: A longitudinal database study of the effect of cash transfer on cure rates. PLoS ONE, 2019, 14, e0212617.	2.5	23
7	Challenges with scale-up of GeneXpert MTB/RIFÂ® in Uganda: a health systems perspective. BMC Health Services Research, 2020, 20, 162.	2.2	23
8	Message to world leaders: we cannot end tuberculosis without addressing the social and economic burden of the disease. The Lancet Global Health, 2018, 6, e1272-e1273.	6.3	17
9	Feasibility of a short message service (SMS) intervention to deliver tuberculosis testing results in peri-urban and rural Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 16, 100110.	1.3	15
10	Outlook for tuberculosis elimination in California: An individual-based stochastic model. PLoS ONE, 2019, 14, e0214532.	2.5	15
11	Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). Implementation Science, 2020, 15, 24.	6.9	14
12	Introducing risk inequality metrics in tuberculosis policy development. Nature Communications, 2019, 10, 2480.	12.8	13
13	Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 356-365.	5.6	13
14	Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis. New England Journal of Medicine, 2021, 385, 2441-2450.	27.0	13
15	Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 18, 100136.	1.3	12
16	State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity. PLoS ONE, 2021, 16, e0249012.	2.5	11
17	Modeling the Impact of Recommendations for Primary Careâ€“Based Screening for Latent Tuberculosis Infection in California. Public Health Reports, 2020, 135, 172S-181S.	2.5	10
18	Costs incurred by patients with drug-susceptible pulmonary tuberculosis in semi-urban and rural settings of Western India. Infectious Diseases of Poverty, 2020, 9, 144.	3.7	10

#	Article	IF	Citations
19	The University of California San Francisco (UCSF) Training Program in Implementation Science: Program Experiences and Outcomes. Frontiers in Public Health, 2020, 8, 94.	2.7	7
20	Quality of care for patients evaluated for tuberculosis in the context of Xpert MTB/RIF scale-up. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 15, 100099.	1.3	6
21	Patient Perspectives and Willingness to Accept Incentives for Tuberculosis Diagnostic Evaluation in Uganda. Value in Health Regional Issues, 2021, 25, 48-56.	1.2	6
22	Readiness to implement on-site molecular testing for tuberculosis in community health centers in Uganda. Implementation Science Communications, 2022, 3, 9.	2.2	4
23	Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. Diagnostics, 2019, 9, 56.	2.6	2
24	Economic analyses to inform public health decision-making for tuberculosis: the role of understanding implementation. BMC Medicine, 2019, 17, 224.	5.5	2
25	Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination. Public Health Reports, 2020, 135, 38S-43S.	2.5	2
26	The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology, 2022, 33, 75-83.	2.7	2
27	Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States. Annals of the American Thoracic Society, 2020, 17, 1639-1642.	3.2	2
28	Measuring success: The challenge of social protection in helping eliminate tuberculosis. PLoS Medicine, 2017, 14, e1002419.	8.4	0